More in the new LAAC focus issue of #JACC: https://bit.ly/4iJ8Mjr
#CardioSky #JACC
More in the new LAAC focus issue of #JACC: https://bit.ly/4iJ8Mjr
#CardioSky #JACC
#CardioSky @bbikdeli.bsky.social
#CardioSky @bbikdeli.bsky.social
Read more in the #LAAC issue of #JACC: https://bit.ly/4AjVwst
Read more in the #LAAC issue of #JACC: https://bit.ly/4AjVwst
honored to talk to @hmkyale.bsky.social RE @jaccjournals.bsky.social papers.
📹 here: youtu.be/8uy8wbnTEog
📝 here: jacc.org/doi/10.1016/j.jacc.2026.09.018
And the full issue here: jacc.org/special-collection/laac
honored to talk to @hmkyale.bsky.social RE @jaccjournals.bsky.social papers.
📹 here: youtu.be/8uy8wbnTEog
📝 here: jacc.org/doi/10.1016/j.jacc.2026.09.018
And the full issue here: jacc.org/special-collection/laac
Read more: https://bit.ly/4AdRF0h #CardioSky
View the data: qrco.de/bh4jKW
View the data: qrco.de/bh4jKW
Read more: https://bit.ly/4AdRF0h #CardioSky
Read more: https://bit.ly/4AdRF0h #CardioSky
米国、LAACに成功の1.857例 [平均76歳] ランダム化——
・6カ月間の「死亡・脳卒中/塞栓症・大出血」発生率は、DPAT
6.9%、減量DOAC 5.1%、アスピリン単剤 3.3%。
・ASAのみDAPTと有意差。
・DOAC、ASAともDAPTに非劣性。
全文🔗 qr.paps.jp/8GHwk
米国、LAACに成功の1.857例 [平均76歳] ランダム化——
・6カ月間の「死亡・脳卒中/塞栓症・大出血」発生率は、DPAT
6.9%、減量DOAC 5.1%、アスピリン単剤 3.3%。
・ASAのみDAPTと有意差。
・DOAC、ASAともDAPTに非劣性。
全文🔗 qr.paps.jp/8GHwk
- THE NET ADVANCE OF PHYSICS
web.mit.edu/redingtn/www...
- Educational Resources page of the LSC Academic Advisory Committee
wiki.ligo.org/LAAC/Educati...
- THE NET ADVANCE OF PHYSICS
web.mit.edu/redingtn/www...
- Educational Resources page of the LSC Academic Advisory Committee
wiki.ligo.org/LAAC/Educati...
Suite 👉 https://monumentum.fr/musee-de-france/m0620/dunkerque-musee-dart-contemporain
Suite 👉 https://monumentum.fr/musee-de-france/m0620/dunkerque-musee-dart-contemporain
Learn more about SIMPLAAFY: qrco.de/bh3JTQ
Learn more about SIMPLAAFY: qrco.de/bh3JTQ
Explore related studies through structured, visual Briefs on CurrentCardio:
currentcardio.com/explore/?q=L...
Explore related studies through structured, visual Briefs on CurrentCardio:
currentcardio.com/explore/?q=L...
➡️ https://l.leparisien.fr/lAAC
➡️ https://l.leparisien.fr/lAAC
A new Europace review reconciles them: the benefit depends on the patient, not just the device.
• CHAMPION-like: lower bleeding risk, long life expectancy
• CLOSURE-like: frail, multimorbid, high competing mortality
A new Europace review reconciles them: the benefit depends on the patient, not just the device.
• CHAMPION-like: lower bleeding risk, long life expectancy
• CLOSURE-like: frail, multimorbid, high competing mortality
www.youtube.com/watch?v=lAac...
www.youtube.com/watch?v=lAac...
⏬Download the full white paper from MedAxiom: qrco.de/bh1Z4G
⏬Download the full white paper from MedAxiom: qrco.de/bh1Z4G
Proven Performance. Predictable Outcomes.
Proven Performance. Predictable Outcomes.